{"id":70503,"date":"2026-07-23T21:42:02","date_gmt":"2026-07-23T13:42:02","guid":{"rendered":"https:\/\/flcube.com\/?p=70503"},"modified":"2026-07-23T21:42:03","modified_gmt":"2026-07-23T13:42:03","slug":"pfizer-secures-fda-priority-review-for-talzenna-xtandi-combination-in-earlier-stage-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70503","title":{"rendered":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced on July 22, 2026 that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for <strong>Priority Review<\/strong> a <strong>supplemental New Drug Application (sNDA)<\/strong> for the combination of <strong>TALZENNA\u00ae (talazoparib)<\/strong> and <strong>XTANDI\u00ae (enzalutamide)<\/strong> for the treatment of men with <strong>homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Pfizer Inc. (NYSE: PFE)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>sNDA accepted for Priority Review<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>22 Jul 2026<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>HRR gene-altered mCSPC (metastatic hormone-sensitive prostate cancer)<\/td><\/tr><tr><td><strong>Current Approval<\/strong><\/td><td>HRR gene-mutated mCRPC (metastatic castration-resistant prostate cancer)<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority Review (6-month timeline vs. standard 10-month)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-talzenna-talazoparib\" class=\"wp-block-heading\">TALZENNA\u00ae (talazoparib)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: Oral poly ADP-ribose polymerase (PARP) inhibitor<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Exploits synthetic lethality in HRR-deficient cancer cells<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Once-daily oral tablet<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-xtandi-enzalutamide\" class=\"wp-block-heading\">XTANDI\u00ae (enzalutamide)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: Androgen receptor pathway inhibitor (ARPI)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Blocks androgen receptor signaling critical for prostate cancer growth<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Once-daily oral capsule<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-combination-rationale\" class=\"wp-block-heading\">Combination Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Pathway Inhibition<\/strong>: Simultaneous targeting of DNA repair deficiency (PARP) and androgen signaling (ARPI)<\/li>\n\n\n\n<li><strong>Precision Medicine Approach<\/strong>: Specifically indicated for patients with HRR gene alterations<\/li>\n\n\n\n<li><strong>Disease Stage Expansion<\/strong>: Moves treatment paradigm from castration-resistant to castration-sensitive disease<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-commercial-significance\" class=\"wp-block-heading\">Clinical &amp; Commercial Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Earlier Intervention<\/strong>: Potential to treat prostate cancer at mCSPC stage, representing earlier disease progression than current mCRPC indication<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Approximately 20-25% of mCSPC patients harbor HRR gene alterations, creating addressable market of 8,000-10,000 new U.S. patients annually<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: First PARP inhibitor combination seeking approval in mCSPC setting, establishing potential first-mover advantage<\/li>\n\n\n\n<li><strong>Revenue Impact<\/strong>: Could extend TALZENNA-XTANDI commercial lifecycle by capturing earlier-stage patients before progression to mCRPC<\/li>\n\n\n\n<li><strong>Standard of Care Evolution<\/strong>: May redefine treatment algorithms for biomarker-selected mCSPC patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Oncology Leadership<\/strong>: Reinforces Pfizer&#8217;s commitment to biomarker-driven prostate cancer therapies<\/li>\n\n\n\n<li><strong>Lifecycle Management<\/strong>: Extends commercial opportunity for both TALZENNA and XTANDI through indication expansion<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: Addresses unmet need for targeted therapies in earlier-stage metastatic prostate cancer<\/li>\n\n\n\n<li><strong>Healthcare Economics<\/strong>: Earlier intervention may reduce long-term healthcare costs associated with disease progression and complications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review, clinical development, and commercial potential. Actual results may differ due to risks including FDA review outcomes, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70504,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,29,38,863,309],"class_list":["post-70503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-combination-therapy","tag-market-approval-filings","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70503\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70503\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T13:42:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T13:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer\",\"datePublished\":\"2026-07-23T13:42:02+00:00\",\"dateModified\":\"2026-07-23T13:42:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2302.webp\",\"keywords\":[\"Cancer\",\"Combination therapy\",\"Market approval filings\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70503#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70503\",\"name\":\"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2302.webp\",\"datePublished\":\"2026-07-23T13:42:02+00:00\",\"dateModified\":\"2026-07-23T13:42:03+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70503\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70503#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70503","og_locale":"en_US","og_type":"article","og_title":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer","og_description":"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).","og_url":"https:\/\/flcube.com\/?p=70503","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T13:42:02+00:00","article_modified_time":"2026-07-23T13:42:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70503#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70503"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer","datePublished":"2026-07-23T13:42:02+00:00","dateModified":"2026-07-23T13:42:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70503"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70503#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","keywords":["Cancer","Combination therapy","Market approval filings","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70503#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70503","url":"https:\/\/flcube.com\/?p=70503","name":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70503#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70503#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","datePublished":"2026-07-23T13:42:02+00:00","dateModified":"2026-07-23T13:42:03+00:00","description":"Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for the combination of TALZENNA\u00ae (talazoparib) and XTANDI\u00ae (enzalutamide) for the treatment of men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70503#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70503"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70503#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","width":1080,"height":608,"caption":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70503#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70503"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70503\/revisions"}],"predecessor-version":[{"id":70505,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70503\/revisions\/70505"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70504"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}